This study confirmed the safety and feasibility of using the Inje cocktail to assess the in vivo activity of CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in women receiving chemotherapy for breast cancer (BC). This evidence concerns the gene CYP3A4 and breast carcinoma.